255 related articles for article (PubMed ID: 24387318)
1. Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis.
Czaja AJ
Aliment Pharmacol Ther; 2014 Feb; 39(4):385-406. PubMed ID: 24387318
[TBL] [Abstract][Full Text] [Related]
2. Targeting Hepatic Fibrosis in Autoimmune Hepatitis.
Montano-Loza AJ; Thandassery RB; Czaja AJ
Dig Dis Sci; 2016 Nov; 61(11):3118-3139. PubMed ID: 27435327
[TBL] [Abstract][Full Text] [Related]
3. Reversal of liver cirrhosis in autoimmune hepatitis.
Shah AM; Malhotra A; Kothari S; Baddoura W; Depasquale J; Spira R
Hepatogastroenterology; 2011; 58(112):2115-7. PubMed ID: 22234080
[TBL] [Abstract][Full Text] [Related]
4. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy.
Cotler SJ; Jakate S; Jensen DM
J Clin Gastroenterol; 2001; 32(5):428-30. PubMed ID: 11319316
[TBL] [Abstract][Full Text] [Related]
5. [An infant of autoimmune hepatitis (type I) with cirrhosis].
Nakashima S; Kurozumi H; Imagawa T; Miyamae T; Ito S; Inui A; Fujisawa T; Yokota S
Ryumachi; 1999 Aug; 39(4):651-6. PubMed ID: 10536482
[TBL] [Abstract][Full Text] [Related]
6. Management of Difficult Cases of Autoimmune Hepatitis.
Lammert C; Loy VM; Oshima K; Gawrieh S
Curr Gastroenterol Rep; 2016 Feb; 18(2):9. PubMed ID: 26780632
[TBL] [Abstract][Full Text] [Related]
7. Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis.
Czaja AJ
Aliment Pharmacol Ther; 2014 May; 39(10):1043-58. PubMed ID: 24628539
[TBL] [Abstract][Full Text] [Related]
8. Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis.
Czaja AJ; Montano-Loza AJ
Dig Dis Sci; 2019 Feb; 64(2):324-344. PubMed ID: 30370494
[TBL] [Abstract][Full Text] [Related]
9. Evolving paradigm of treatment for autoimmune hepatitis.
Czaja AJ
Expert Rev Clin Immunol; 2017 Aug; 13(8):781-798. PubMed ID: 28406324
[TBL] [Abstract][Full Text] [Related]
10. Hepatic stellate cell activation and hepatic fibrosis in children with type 1 autoimmune hepatitis: an immunohistochemical study of paired liver biopsies before treatment and after clinical remission.
Maia JM; Maranhão Hde S; Sena LV; Rocha LR; Medeiros IA; Ramos AM
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):264-9. PubMed ID: 20009940
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of patients with autoimmune hepatitis induced cirrhosis after immunosuppressive treatment.
Hatoum S; Rockey DC
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):742-749. PubMed ID: 38555597
[TBL] [Abstract][Full Text] [Related]
12. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis.
Mohamadnejad M; Malekzadeh R; Nasseri-Moghaddam S; Hagh-Azali S; Rakhshani N; Tavangar SM; Sedaghat M; Alimohamadi SM
Dig Dis Sci; 2005 Mar; 50(3):547-51. PubMed ID: 15810640
[TBL] [Abstract][Full Text] [Related]
13. Hepatic inflammation and progressive liver fibrosis in chronic liver disease.
Czaja AJ
World J Gastroenterol; 2014 Mar; 20(10):2515-32. PubMed ID: 24627588
[TBL] [Abstract][Full Text] [Related]
14. Liver dysfunction and fibrosis as predictors of biochemical response to autoimmune hepatitis treatment.
Soares JC; Borgonovo A; Maggi DC; Pasinato AP; Ramos FG; Dantas-Corrêa EB; Schiavon LL; Narciso-Schiavon JL
Minerva Gastroenterol Dietol; 2016 Jun; 62(2):138-47. PubMed ID: 27091035
[TBL] [Abstract][Full Text] [Related]
15. Platelet count to spleen diameter ratio non-invasively identifies severe fibrosis and cirrhosis in patients with autoimmune hepatitis.
Sheptulina A; Shirokova E; Nekrasova T; Blum H; Ivashkin V
J Gastroenterol Hepatol; 2016 Dec; 31(12):1956-1962. PubMed ID: 27059170
[TBL] [Abstract][Full Text] [Related]
16. [Histological regression of liver fibrosis with immunosuppressive therapy in autoimmune hepatitis].
Valera JM; Smok G; Márquez S; Poniachik J; Brahm J
Gastroenterol Hepatol; 2011 Jan; 34(1):10-5. PubMed ID: 21194803
[TBL] [Abstract][Full Text] [Related]
17. Reversibility of hepatic fibrosis in autoimmune hepatitis.
Dufour JF; DeLellis R; Kaplan MM
Ann Intern Med; 1997 Dec; 127(11):981-5. PubMed ID: 9412303
[TBL] [Abstract][Full Text] [Related]
18. microRNA-143-3p attenuated development of hepatic fibrosis in autoimmune hepatitis through regulation of TAK1 phosphorylation.
Tu H; Chen D; Cai C; Du Q; Lin H; Pan T; Sheng L; Xu Y; Teng T; Tu J; Lin Z; Wang X; Wang R; Xu L; Chen Y
J Cell Mol Med; 2020 Jan; 24(2):1256-1267. PubMed ID: 31808606
[TBL] [Abstract][Full Text] [Related]
19. [Genetic risk factors for hepatic fibrosis in chronic liver diseases].
Wasmuth HE; Lammert F; Matern S
Med Klin (Munich); 2003 Dec; 98(12):754-62. PubMed ID: 14685677
[TBL] [Abstract][Full Text] [Related]
20. Complete regression of cirrhosis after immunosuppressive treatment in autoimmune hepatitis.
Ustundag G; Kuloglu Z; Kirsaçlioğlu CT; Kansu A; Erden E; Girgin N
Pediatr Int; 2008 Oct; 50(5):711-3. PubMed ID: 19261129
[No Abstract] [Full Text] [Related]
[Next] [New Search]
